Journal article
Prospective evaluation of anti-tumor necrosis factor therapy guided by magnetic resonance imaging for crohn's perineal fistulas
SC Ng, S Plamondon, A Gupta, D Burling, A Swatton, CJ Vaizey, MA Kamm
American Journal of Gastroenterology | Published : 2009
DOI: 10.1038/ajg.2009.509
Abstract
OBJECTIVES: Anti-tumor necrosis factor (TNF) therapy heals Crohn's fistulas clinically, but the rate, extent, and duration to achieve fistula track healing are unknown. METHODS: We sought to monitor deep healing, as indicated by magnetic resonance imaging (MRI), and to use this to determine treatment duration. Clinical and MRI fistula healing (at 6, 12, and 18 months), Crohn's Disease Activity Index (CDAI), Perianal Crohn's Disease Activity Index (PDAI), and the Inflammatory Bowel Disease Questionnaire were prospectively assessed. RESULTS: Thirty-four consecutive patients with perineal fistulas were treated with infliximab (19), adalimumab (7; all infliximab failures) and thalidomide (8). Me..
View full abstractGrants
Funding Acknowledgements
This study was partly funded by an unrestricted educational grant from Schering-Plough UK. Schering-Plough UK had no knowledge of the nature, content, or results of the study. Michael Kamm has acted as consultant to, speaker for, or received research support from Abbott, Centocor, Schering- Plough, and UCB.